HOLLISTON, Mass., Oct. 13, 2016 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its third quarter 2016 after market trading hours on Thursday, October 27, 2016. A conference call to discuss the company's third quarter 2016 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4540, or international: 1-847-619-6397, and referencing the conference ID# 43551089.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at: http://investor.harvardbioscience.com/ and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through November 3, 2016.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACTS: Jeffrey A. Duchemin CEO and President Robert E. Gagnon CFO Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Washington Post Publisher Will Lewis Steps Down After Layoffs 



